RA Capital Management
Overview
RA Capital Management is a multi-stage investment manager that focuses on evidence-based investing in public and private healthcare and life science companies developing drugs, medical devices, diagnostics, services, and research tools.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Celea Therapeutics | Jul 2026 | Seed | Co-investor |
| Ollin Biosciences | Jun 2026 | Series B | Co-investor |
| NorthLinks Bio | Jun 2026 | Series A | Lead |
| Serapha Bio | Jun 2026 | Series A | Lead |
| cAMPfield Therapeutics | Jun 2026 | Series A | Co-investor |
Key People
Brigid O'Brien
Managing Partner, Planetary Health
Kyle Teamey
Managing Partner, Planetary Health
Peter Kolchinsky
Managing Partner
Emmanuel Bassey
Senior Partner
Genevieve Cross
Senior Partner
Suvendu Pal
Senior Partner
Adam Kaye
Senior Managing Director And Partner, Structured Capital
Joshua Resnick
Partner And Senior Managing Director
Laura Tadvalkar
Managing Director
Nandita Shangari
Managing Director
Vreni Schoenenberger
Managing Director, External Affairs
Fanny Cavalie
Venture Partner
Habib Dable
Venture Partner (Part-Time)
Mario Barro
Venture Partner And Head Of Infectious Diseases At RA Capital
Mark Boshar
Venture Partner
Milind Kamkolkar
Venture Partner
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
